Today, the reporter learned from the Second People's Hospital of Shenzhen (hereinafter referred to as the Second Hospital of Shenzhen) that recently, the Second Hospital of the City introduced the hepatobiliary center team of Academician Wang Xuehao of the First Affiliated Hospital of Nanjing Medical University through the "Three Medical and Health Projects", and under the leadership and guidance of Academician Wang Xuehao, YTHDF1 was found to be a potential prognostic biomarker and treatment target for HCC patients.
The paper, with Academician Wang Xuehao as the corresponding author and Professor Ni Yong as the co-first author (ranked second), was published, providing new ideas for the treatment of liver cancer.
Significant overexpression of YTHDF1 in HCC tissue was found to be associated with poor prognosis. This study has created several "firsts", including the first to reveal that the high expression of YTHDF1 in HCC is related to the transcriptional regulation of the hypoxia inducible factor HIF1α, and the first to show that YTHDF1 can promote the translation of autophagy-related proteins ATG2A and ATG14 by specifically identifying methylation modification sites, thereby promoting hypoxia-induced autophagy and autophagy-related malignant biological behavior. This also confirms that YTHDF1 is a potential prognostic biomarker and therapeutic target for patients with HCC.
According to reports, the Hepatobiliary Center of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) is a research-oriented clinical medical center, a key clinical specialty of the National Health Commission, the Key Laboratory of Liver Transplantation of the Chinese Academy of Medical Sciences, one of the top ten clinical medical centers in Jiangsu Province, and a national liver cancer diagnosis and treatment center in Jiangsu, which enjoys a high reputation at home and abroad. The discipline leader is Professor Wang Xuehao, academician of the Chinese Academy of Engineering, a well-known expert in organ transplantation and hepatobiliary surgery in China, a pioneer of living liver transplantation in China, one of the pioneers of modern interventional treatment of liver cancer in the world, and a pioneer in the interventional treatment of liver cancer in China. In recent years, the center has won 1 major national research and development plan, 2 key projects of the National Natural Science Foundation, a total of 33 projects of the National Natural Science Foundation, and a total of about 80 million yuan of funding for national, provincial and ministerial science and technology projects; published more than 400 SCI papers in many magazines; and won more than 10 national science and technology progress awards and provincial and ministerial awards.
Text/Guangzhou Daily, New Flower City Reporter: Xuan Hui
Guangzhou Daily • New Flower City Editor: Tong Dan
![The fame of Gu Ailing in the Beijing Winter Olympics has attracted the attention of many people. Gu Ailing is not only the world's ski genius, but also a bully at Stanford University, and everyone guesses that she must not have made up lessons! valley[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)